Morroniside _MMP 抑制劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMorronisideCat. No.: HY-N0532CAS No.: 25406-64-8分式: CHO分量: 406.38作靶點(diǎn): MMP; Apoptosis作通路: Metabolic Enzyme/Protease; Apoptosis儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 125 mg/mL (307.5

2、9 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.4608 mL 12.3038 mL 24.6075 mL5 mM 0.4922 mL 2.4608 mL 4.9215 mL10 mM 0.2461 mL 1.2304 mL 2.4608 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清

3、的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (5.12 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (5.12 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.08 mg

4、/mL (5.12 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Morroniside 通過(guò)抑制神經(jīng)元凋亡和 MMP9/2 的表達(dá)從發(fā)揮神經(jīng)保護(hù)作。IC50 & Target MMP2 MMP9體內(nèi)研究 Morroniside reduces the expression of MMP2 and MMP9 in an I/R injury model. Treatment with Morronisidesignificantly reduces I/Ras

5、sociated neuron apoptosis in a dose dependent m anner. The results dem onstrate that activecaspase3 and Bax are significantly upregulated in the m odel group com pared with the control group, while Bcl2 issignificantly downregulated. The expression of active caspase3 and Bax is significantly downreg

6、ulated by Morronisidetreatm ent in a dosedependent m anner, while the expression of Bcl2 is significantly upregulated 1. Morroniside hasan am eliorative effect on diabetes-induced alterations such as oxidative stress, inflam m ation, and apoptosis in the liverof type 2 diabetic db/db m ice 2.PROTOCO

7、LAnimal Rats 1Administration 1 A total of 50 adult male Sprague Dawley rats (age, 7 8 weeks; weight, 260 280 g) are used. Rats arerandomly assigned into five groups (n=10 in each). Rats in the control group undergo sham surgery. All otherrats undergo suture occluded surgery, with a 0.26 mm nylon mon

8、ofilament inserted through the rightcommon carotid artery and are divided into groups as follows: The cerebral I/R injury model group (model),no treatment; low dose group, 30 mg/kg/day Morroniside by gavage; moderate dose group, 90 mg/kg/dayMorroniside by gavage; high dose group, 270 mg/kg/day Morro

9、niside by gavage. Rats in the control andmodel groups receive an equal volume of normal saline 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Zeng G, et al. Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting

10、neuron apoptosis and MMP2/9 expression.Exp Ther Med. 2018 Sep;16(3):2229-2234.2. Park CH, et al. Evaluation of morroniside, iridoid glycoside from Corni Fructus, on diabetes-induced alterations such as oxidative stress,inflammation, and apoptosis in the liver of type 2 diabetic db/db mice. Biol Pharm Bull. 2011;34(10):1559-65.McePdfHeightCaution: Product has not been fully va